Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27397549 | 0.92 | SIGMAR1 (0.55) | SIGMAR1ALDH1A1TSHRPAOXKDM4E | |
| SCHEMBL20438446 | 0.91 | PIK3CD (0.40) | SIGMAR1ALDH1A1 | |
| SCHEMBL20665990 | 0.88 | SIGMAR1 (0.36) | SIGMAR1ALDH1A1TSHRPAOXKDM4E | |
| SCHEMBL16258898 | 0.85 | SIGMAR1 (0.44) | SIGMAR1ALDH1A1TSHRPAOXKDM4E | |
| SCHEMBL21653737 | 0.83 | SIGMAR1 (0.42) | SIGMAR1ALDH1A1TSHRPAOXKDM4E | |
| SCHEMBL27397723 | 0.83 | CYP2D6 (0.41) | SIGMAR1ALDH1A1TSHRCYP1A2CYP2C19 | |
| SCHEMBL24220956 | 0.83 | HSD17B10 (0.47) | SIGMAR1ALDH1A1KDM4ETDP1 | |
| SCHEMBL21764427 | 0.83 | HSD17B10 (0.47) | SIGMAR1ALDH1A1KDM4ETDP1 | |
| SCHEMBL20202265 | 0.83 | HSD17B10 (0.47) | SIGMAR1ALDH1A1KDM4ETDP1 | |
| SCHEMBL10284339 | 0.83 | HSD17B10 (0.47) | SIGMAR1ALDH1A1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230146870-A1 | METHOD TO QUANTIFY AFFINITY AND SELECTIVITY OF SMALL MOLECULES FOR PROTEINS IN LIVING CELLS | OHIO STATE INNOVATION FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| EP-3497094-B1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-02-15 | — | — | EP | disclosed |
| WO-2022123462-A1 | RADIOLABELLED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-06-16 | — | — | WO | disclosed |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| WO-2021154669-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-05 | — | — | WO | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| WO-2021097299-A1 | METHODS AND COMPOSITIONS FOR SMOKING CESSATION | BEHAVIORAL DIAGNOSTICS, LLC (US) | 2021-05-20 | — | — | WO | disclosed |
| US-10947214-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| US-10934280-B2 | Condensed thiophene derivatives useful as NaPi-IIb inhibitors | ELI LILLY AND COMPANY (US) | 2021-03-02 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221216-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| WO-2010096462-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010091413-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20090170845-A1 | USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | AEGERA THERAPEUTICS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20090036357-A1 | Azapeptide derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| US-20070112043-A1 | Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof | AEGERA THERAPEUTICS, INC. (CA) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170845-A1 | USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | SCN1B, SCN3A, SCN1A | SIGMAR1 47/4885ALDH1A1 658/4885TSHR 1370/4885 |
| US-20070112043-A1 | Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof | AADAC, NAT1, PMP22 | SIGMAR1 180/4885ALDH1A1 132/4885TSHR 2054/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | SIGMAR1 1110/4885ALDH1A1 1144/4885TSHR 4635/4885 |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | SIGMAR1 1110/4885ALDH1A1 1144/4885TSHR 4635/4885 |
| US-10934280-B2 | Condensed thiophene derivatives useful as NaPi-IIb inhibitors | SLC34A2, ALPI, SLC34A1 | SIGMAR1 2354/4885ALDH1A1 3142/4885TSHR 2507/4885 |
| US-20090036357-A1 | Azapeptide derivatives | SAMHD1, ENTPD5, DNPEP | SIGMAR1 4472/4885ALDH1A1 3218/4885TSHR 4817/4885 |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | SIGMAR1 1575/4885ALDH1A1 2100/4885TSHR 655/4885 |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | SIGMAR1 1575/4885ALDH1A1 2100/4885TSHR 655/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | SIGMAR1 2209/4885ALDH1A1 287/4885TSHR 4730/4885 |
| US-20100221216-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | SIGMAR1 1216/4885ALDH1A1 365/4885TSHR 4687/4885 |
| US-10947214-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | SIGMAR1 581/4885ALDH1A1 2465/4885TSHR 744/4885 |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | SIGMAR1 1110/4885ALDH1A1 1144/4885TSHR 4635/4885 |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | SIGMAR1 4538/4885ALDH1A1 4230/4885TSHR 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.